BCL6 and leukemia: Thus, contrary to currently held views that stemness features critically underlie drug resistance in KMT2A-r leukemias, we found that upon targeting their cell cycle control vulnerability, the drug-tolerant cells corresponded to a more differentiated phenotype with expression of pre-BCR and BCL6.